Clinical Trial Update: Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial investigating radioimmunotherapy with 111In/225Actinium-DOTA-daratumumab for relapsed/refractory multiple myeloma is currently recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• 111In/225Actinium-DOTA-daratumumab
• Daratumumab (daratumumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 1 | Status: RECRUITING